Circulating levels of PMN-promoting factors (S100A8/A9, tumor-derived exosomes), protease expression profiles at the primary site (cathepsin S for brain tropism), or imaging biomarkers identifying premetastatic organ changes should guide patient enrollment in these trials [3,90]. The gene discussed is CTSS; the disease is neoplasm.